首页 > 最新文献

Journal of insurance medicine (New York, N.Y.)最新文献

英文 中文
Varicose Veins as Model for Apportionment among Risk Factors for Compensation Purposes. 静脉曲张作为赔偿风险因素的分摊模型。
Q3 Medicine Pub Date : 2024-11-01 DOI: 10.17849/insm-51-3-1-9.2
Marc J Weber, Mark I Taragin

Objective.—: To demonstrate a method which is being used to apportion between risk factors for occupationally related disease and compensate individuals with multiple risk factors. The application to individuals will be demonstrated for varicose veins.

Background.—: The National Insurance Institute (NII) is tasked with compensating work related injuries and illness in Israel. Population attributable fraction (PAF) has been utilized in order to estimate the amount of disease that can potentially be eliminated in a population through the elimination of individual risk factors. PAF is based on relative risks and the prevalence of these risks.

Methods.—: A review of the medical literature consisting of epidemiological studies of varicose veins and its multiple risk factors was conducted, with special attention to prolonged occupational standing. Summary, weighted, relative risks were calculated for eight different risk factors. The proposed formula then allowed for apportioning among those risk factors in the individual.

Results.—: The findings of the current study indicate that prolonged standing may be associated with the presence of varicose veins, however in light of the multiple other risk factors associated, its overall contribution is generally minor.

Conclusion.—: Apportionment among multiple risk factors for varicose veins can be accomplished mathematically in individuals. This application is being applied successfully for other diseases as well.

目标:展示一种方法,该方法被用于分摊与职业有关的疾病的风险因素,并对具有多种风险因素的个人进行补偿。背景:国家保险研究所(NII)的任务是对与工作有关的工伤和职业病进行赔偿:国家保险研究所(NII)的任务是对以色列的工伤和疾病进行赔偿。人口可归因分数(PAF)被用来估算通过消除个人风险因素而可能在人口中消除的疾病数量。PAF 基于相对风险和这些风险的发生率:对有关静脉曲张及其多种风险因素的流行病学研究的医学文献进行了回顾,并特别关注了长期职业性站立。针对八种不同的风险因素,计算了加权相对风险汇总。然后,根据拟议的公式对这些风险因素在个人中进行分摊:目前的研究结果表明,长时间站立可能与静脉曲张的存在有关,但考虑到与之相关的其他多种风险因素,其总体影响一般较小:结论:静脉曲张的多种风险因素可以通过数学方法在个人身上进行分摊。这种应用也成功地应用于其他疾病。
{"title":"Varicose Veins as Model for Apportionment among Risk Factors for Compensation Purposes.","authors":"Marc J Weber, Mark I Taragin","doi":"10.17849/insm-51-3-1-9.2","DOIUrl":"10.17849/insm-51-3-1-9.2","url":null,"abstract":"<p><strong>Objective.—: </strong>To demonstrate a method which is being used to apportion between risk factors for occupationally related disease and compensate individuals with multiple risk factors. The application to individuals will be demonstrated for varicose veins.</p><p><strong>Background.—: </strong>The National Insurance Institute (NII) is tasked with compensating work related injuries and illness in Israel. Population attributable fraction (PAF) has been utilized in order to estimate the amount of disease that can potentially be eliminated in a population through the elimination of individual risk factors. PAF is based on relative risks and the prevalence of these risks.</p><p><strong>Methods.—: </strong>A review of the medical literature consisting of epidemiological studies of varicose veins and its multiple risk factors was conducted, with special attention to prolonged occupational standing. Summary, weighted, relative risks were calculated for eight different risk factors. The proposed formula then allowed for apportioning among those risk factors in the individual.</p><p><strong>Results.—: </strong>The findings of the current study indicate that prolonged standing may be associated with the presence of varicose veins, however in light of the multiple other risk factors associated, its overall contribution is generally minor.</p><p><strong>Conclusion.—: </strong>Apportionment among multiple risk factors for varicose veins can be accomplished mathematically in individuals. This application is being applied successfully for other diseases as well.</p>","PeriodicalId":39345,"journal":{"name":"Journal of insurance medicine (New York, N.Y.)","volume":" ","pages":"129-137"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142297609","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Beware the Black Widow at Claim Time: A Report of Three Cases. 当心索赔时的黑寡妇:三个案例的报告。
Q3 Medicine Pub Date : 2024-11-01 DOI: 10.17849/insm-51-3-1-6.2
Vera F Dolan

Moral hazard is well known to life insurance underwriters and medical directors to increase the risk of adverse consequences to insured individuals. The underwriting investigation of proposed insureds at time of policy issue is done to ensure no likely moral hazard exists. However, not all situations involving moral hazard may be identified at time of underwriting and policy issue, and may only be identified at time of claim. Three cases that were underwritten for life expectancies in legal matters are described here as examples of moral hazard identified at time of severe injury and/or death. All three of these cases involved a woman who manipulated her male partner into situations that increased the man's risk of severe injury and/or death to the woman's financial benefit. Such "black widows" made a great deal of effort over an extensive period of time to ensure that the moral hazard set up for their male partners resulted in a substantial financial windfall through litigation. The moral hazard set up by a black widow thus can be considered by the life insurance industry as sufficiently anti-selective and speculative to deny a claim at any time after policy issue.

人寿保险承保人和医务主任都知道,道德风险会增加投保人遭受不利后果的风险。在签发保单时对拟投保人进行核保调查,以确保不存在可能的道德风险。然而,并非所有涉及道德风险的情况都能在核保和签发保单时发现,可能只有在索赔时才能发现。这里介绍三个在法律事务中为预期寿命承保的案例,作为在严重伤害和/或死亡时发现道德风险的例子。所有这三个案例都涉及一名妇女操纵她的男性伴侣,使其陷入增加男性严重受伤和/或死亡风险的境地,从而使该妇女获得经济利益。这些 "黑寡妇 "在很长一段时间内做出了巨大努力,以确保为其男性伴侣设置的道德风险能够通过诉讼获得巨额经济利益。因此,人寿保险业认为,"黑寡妇 "设置的道德风险具有足够的反选择性和投机性,足以在保单签发后的任何时候拒绝理赔。
{"title":"Beware the Black Widow at Claim Time: A Report of Three Cases.","authors":"Vera F Dolan","doi":"10.17849/insm-51-3-1-6.2","DOIUrl":"10.17849/insm-51-3-1-6.2","url":null,"abstract":"<p><p>Moral hazard is well known to life insurance underwriters and medical directors to increase the risk of adverse consequences to insured individuals. The underwriting investigation of proposed insureds at time of policy issue is done to ensure no likely moral hazard exists. However, not all situations involving moral hazard may be identified at time of underwriting and policy issue, and may only be identified at time of claim. Three cases that were underwritten for life expectancies in legal matters are described here as examples of moral hazard identified at time of severe injury and/or death. All three of these cases involved a woman who manipulated her male partner into situations that increased the man's risk of severe injury and/or death to the woman's financial benefit. Such \"black widows\" made a great deal of effort over an extensive period of time to ensure that the moral hazard set up for their male partners resulted in a substantial financial windfall through litigation. The moral hazard set up by a black widow thus can be considered by the life insurance industry as sufficiently anti-selective and speculative to deny a claim at any time after policy issue.</p>","PeriodicalId":39345,"journal":{"name":"Journal of insurance medicine (New York, N.Y.)","volume":" ","pages":"193-198"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142297608","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Chronic Fatigue Syndrome: Challenges for Evaluation. 慢性疲劳综合征:评估的挑战。
Q3 Medicine Pub Date : 2024-11-01 DOI: 10.1029/AAIMEDICINE-D-24-00033.1
Heinrich H Gerhartz
{"title":"Chronic Fatigue Syndrome: Challenges for Evaluation.","authors":"Heinrich H Gerhartz","doi":"10.1029/AAIMEDICINE-D-24-00033.1","DOIUrl":"https://doi.org/10.1029/AAIMEDICINE-D-24-00033.1","url":null,"abstract":"","PeriodicalId":39345,"journal":{"name":"Journal of insurance medicine (New York, N.Y.)","volume":"51 3","pages":"184-192"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142717372","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Survival Benefit of Pancreas Transplantation: Considerations for Insurance Coverage. 胰腺移植的生存益处:保险承保的考虑因素。
Q3 Medicine Pub Date : 2024-11-01 DOI: 10.1029/AAIMEDICINE-D-24-00031.1
Angelika C Gruessner, Rainer W G Gruessner
{"title":"The Survival Benefit of Pancreas Transplantation: Considerations for Insurance Coverage.","authors":"Angelika C Gruessner, Rainer W G Gruessner","doi":"10.1029/AAIMEDICINE-D-24-00031.1","DOIUrl":"https://doi.org/10.1029/AAIMEDICINE-D-24-00031.1","url":null,"abstract":"","PeriodicalId":39345,"journal":{"name":"Journal of insurance medicine (New York, N.Y.)","volume":"51 3","pages":"163-170"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142717410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Non-Physiologic Doses of Androgenic Anabolic Steroids: Mortality and Underwriting Assessment. 非生理性剂量的雄性同化类固醇:死亡率和承保评估。
Q3 Medicine Pub Date : 2024-11-01 DOI: 10.1029/AAIMEDICINE-D-24-00028.1
John R Iacovino

Little evidence based information exists in the medical literature on the mortality of abusers of anabolic androgenic steroids. These individuals range from competitive athletes and body builders to those whose who use physician prescribed mega-doses. Life insurance medical directors have little guidance on how to underwrite these individuals when presented with their applications. A recent article presented a Kaplan-Meir mortality curve accompanied with a control population demonstrating the mortality of these individuals over a 13-year period. Users of non-physiologic doses of anabolic androgenic steroids experience a mortality about two times the expected mortality of the control population. They should be underwritten with ratings commensurate with their anabolic androgenic steroid abuse and demonstrated mortality.

医学文献中几乎没有关于合成代谢雄性类固醇滥用者死亡率的循证信息。这些人既包括竞技运动员和健美运动员,也包括使用医生开具的超大剂量药物的人。人寿保险公司的医学主管对如何承保这些人的申请几乎没有指导。最近的一篇文章展示了一条 Kaplan-Meir 死亡率曲线,并附有一个对照人群,显示了这些人在 13 年间的死亡率。使用非生理剂量合成代谢雄性类固醇者的死亡率约为对照人群预期死亡率的两倍。应根据他们滥用合成代谢雄性类固醇的情况和显示的死亡率对他们进行相应的评级。
{"title":"Non-Physiologic Doses of Androgenic Anabolic Steroids: Mortality and Underwriting Assessment.","authors":"John R Iacovino","doi":"10.1029/AAIMEDICINE-D-24-00028.1","DOIUrl":"https://doi.org/10.1029/AAIMEDICINE-D-24-00028.1","url":null,"abstract":"<p><p>Little evidence based information exists in the medical literature on the mortality of abusers of anabolic androgenic steroids. These individuals range from competitive athletes and body builders to those whose who use physician prescribed mega-doses. Life insurance medical directors have little guidance on how to underwrite these individuals when presented with their applications. A recent article presented a Kaplan-Meir mortality curve accompanied with a control population demonstrating the mortality of these individuals over a 13-year period. Users of non-physiologic doses of anabolic androgenic steroids experience a mortality about two times the expected mortality of the control population. They should be underwritten with ratings commensurate with their anabolic androgenic steroid abuse and demonstrated mortality.</p>","PeriodicalId":39345,"journal":{"name":"Journal of insurance medicine (New York, N.Y.)","volume":"51 3","pages":"171-174"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142717402","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Innovative Strategies and Insurance Consequences for Implementing Universal Health Insurance in the United States. 在美国实施全民健康保险的创新战略和保险后果。
Q3 Medicine Pub Date : 2024-11-01 DOI: 10.1029/AAIMEDICINE-D-24-00014.1
Rainer W G Gruessner

Universal Health Insurance does not exist in the United States for two reasons: (1) there is a general unwillingness to dismantle the historically grown framework of the world's most complex mix of public and private sector health coverage and (2) mere cost considerations. The first concern can be abated by establishing a Universal Health Insurance system which retains many or most of the historically grown infrastructure. Cost containment of such a reform is addressed herein in that the two proposed pathways comprise either (1) a leveled solution through Medicare-expansion for the uninsured only or (2) a more complex solution through a national, 2-tier healthcare system for all Americans. Both pathways are based on solid financing without major tax increases by using existing and/or yet untapped funding sources. The insurance consequences for both options are assessable. They are minor for the Medicare-expansion and more wide-ranging, yet also achievable, for a national, 2-tier healthcare system. Universal Health Insurance must no longer be an illusion that continues to haunt our society in the 21st century.

美国没有全民健康保险有两个原因:(1) 人们普遍不愿意拆除历史上形成的世界上最复杂的公共和私营部门混合健康保险框架;(2) 只是出于成本考虑。建立全民健康保险制度,保留许多或大部分历史上发展起来的基础设施,可以缓解第一种担忧。本文将讨论这种改革的成本控制问题,建议的两种途径包括:(1) 仅通过扩大医疗保险范围为未参保者提供公平的解决方案;(2) 通过为所有美国人建立一个全国性的两级医疗保健系统提供更为复杂的解决方案。这两种方案的基础都是在不大幅增税的情况下,利用现有和/或尚未开发的资金来源进行稳健融资。两种方案的保险后果都是可以评估的。对于扩大医疗保险来说,其影响较小,而对于全国性的两级医疗保健系统来说,其影响范围更广,但也是可以实现的。全民医疗保险决不能再成为 21 世纪继续困扰我们社会的幻想。
{"title":"Innovative Strategies and Insurance Consequences for Implementing Universal Health Insurance in the United States.","authors":"Rainer W G Gruessner","doi":"10.1029/AAIMEDICINE-D-24-00014.1","DOIUrl":"https://doi.org/10.1029/AAIMEDICINE-D-24-00014.1","url":null,"abstract":"<p><p>Universal Health Insurance does not exist in the United States for two reasons: (1) there is a general unwillingness to dismantle the historically grown framework of the world's most complex mix of public and private sector health coverage and (2) mere cost considerations. The first concern can be abated by establishing a Universal Health Insurance system which retains many or most of the historically grown infrastructure. Cost containment of such a reform is addressed herein in that the two proposed pathways comprise either (1) a leveled solution through Medicare-expansion for the uninsured only or (2) a more complex solution through a national, 2-tier healthcare system for all Americans. Both pathways are based on solid financing without major tax increases by using existing and/or yet untapped funding sources. The insurance consequences for both options are assessable. They are minor for the Medicare-expansion and more wide-ranging, yet also achievable, for a national, 2-tier healthcare system. Universal Health Insurance must no longer be an illusion that continues to haunt our society in the 21st century.</p>","PeriodicalId":39345,"journal":{"name":"Journal of insurance medicine (New York, N.Y.)","volume":"51 3","pages":"138-142"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142717399","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Assessing the Pathophysiology, Morbidity, and Mortality of Obstructive Sleep Apnea. 评估阻塞性睡眠呼吸暂停的病理生理学、发病率和死亡率。
Q3 Medicine Pub Date : 2024-11-01 DOI: 10.17849/insm-51-3-1-20.2
R C Richie

The basic definitions of obstructive sleep apnea (OSA), its epidemiology, its clinical features and complications, and the morbidity and mortality of OSA are discussed. Included in this treatise is a discussion of the various symptomatic and polysomnographic phenotypes of COPD that may enable better treatment and impact mortality in persons with OSA. The goal of this article is to serve as a reference for life and disability insurance company medical directors and underwriters when underwriting an applicant with probable or diagnosed sleep apnea. It is well-referenced (133 ref.) allowing for more in-depth investigation of any aspect of sleep apnea being queried.

论述了阻塞性睡眠呼吸暂停(OSA)的基本定义、流行病学、临床特征和并发症,以及 OSA 的发病率和死亡率。本论文还讨论了慢性阻塞性肺疾病的各种症状和多导睡眠图表型,这些表型可帮助更好地治疗 OSA 患者并影响其死亡率。本文旨在为人寿和伤残保险公司的医疗主管和核保人员在核保可能或确诊患有睡眠呼吸暂停的申请人时提供参考。本文参考文献丰富(133 篇参考文献),可对睡眠呼吸暂停的任何方面进行更深入的调查。
{"title":"Assessing the Pathophysiology, Morbidity, and Mortality of Obstructive Sleep Apnea.","authors":"R C Richie","doi":"10.17849/insm-51-3-1-20.2","DOIUrl":"10.17849/insm-51-3-1-20.2","url":null,"abstract":"<p><p>The basic definitions of obstructive sleep apnea (OSA), its epidemiology, its clinical features and complications, and the morbidity and mortality of OSA are discussed. Included in this treatise is a discussion of the various symptomatic and polysomnographic phenotypes of COPD that may enable better treatment and impact mortality in persons with OSA. The goal of this article is to serve as a reference for life and disability insurance company medical directors and underwriters when underwriting an applicant with probable or diagnosed sleep apnea. It is well-referenced (133 ref.) allowing for more in-depth investigation of any aspect of sleep apnea being queried.</p>","PeriodicalId":39345,"journal":{"name":"Journal of insurance medicine (New York, N.Y.)","volume":" ","pages":"143-162"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142548157","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Autoimmune Diseases following COVID-19 Infection: How Solid is the Evidence? 感染 COVID-19 后的自身免疫性疾病:证据有多充分?
Q3 Medicine Pub Date : 2024-11-01 DOI: 10.1029/AAIMEDICINE-D-24-00026.1
Timothy Meagher
{"title":"Autoimmune Diseases following COVID-19 Infection: How Solid is the Evidence?","authors":"Timothy Meagher","doi":"10.1029/AAIMEDICINE-D-24-00026.1","DOIUrl":"https://doi.org/10.1029/AAIMEDICINE-D-24-00026.1","url":null,"abstract":"","PeriodicalId":39345,"journal":{"name":"Journal of insurance medicine (New York, N.Y.)","volume":"51 3","pages":"125-128"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142717368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Long-term Complications of Covid-19 Infection. Covid-19感染的长期并发症
Q3 Medicine Pub Date : 2024-07-09 DOI: 10.17849/insm-51-2-1-4.2
Timothy Meagher

As the Covid-19 pandemic continues into its 4th year, reports of long-term morbidity and mortality are now attracting attention. Recent studies suggest that Covid-19 survivors are at increased risk of common illnesses, such as myocardial infarction, diabetes mellitus and autoimmune disorders. Mortality may also be increased. This article will review the evidence that supports some of these observations and provide an opinion about their validity and their relevance to insured cohorts.

随着 Covid-19 大流行进入第 4 个年头,有关长期发病率和死亡率的报告正引起人们的关注。最近的研究表明,Covid-19 的幸存者罹患心肌梗塞、糖尿病和自身免疫性疾病等常见疾病的风险增加。死亡率也可能增加。本文将回顾支持其中一些观察结果的证据,并就其有效性及其与投保人群的相关性发表看法。
{"title":"The Long-term Complications of Covid-19 Infection.","authors":"Timothy Meagher","doi":"10.17849/insm-51-2-1-4.2","DOIUrl":"https://doi.org/10.17849/insm-51-2-1-4.2","url":null,"abstract":"<p><p>As the Covid-19 pandemic continues into its 4th year, reports of long-term morbidity and mortality are now attracting attention. Recent studies suggest that Covid-19 survivors are at increased risk of common illnesses, such as myocardial infarction, diabetes mellitus and autoimmune disorders. Mortality may also be increased. This article will review the evidence that supports some of these observations and provide an opinion about their validity and their relevance to insured cohorts.</p>","PeriodicalId":39345,"journal":{"name":"Journal of insurance medicine (New York, N.Y.)","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141559959","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Through the Looking Glass Darkly: How May AI Models Influence Future Underwriting? 透过黑暗的望远镜:人工智能模型如何影响未来的核保?
Q3 Medicine Pub Date : 2024-07-01 DOI: 10.17849/insm-51-2-59-63.1
Rodney C Richie

Applications of Artificial Intelligence (AI) deep-learning models to screening for clinical conditions continue to evolve. Instances provided in this treatise include using a simple one-view PA chest radiograph to screen for Type 2 Diabetes Mellitus (T2DM), congestive heart failure, valvular heart disease, and to assess mortality in asymptomatic persons with respiratory diseases. This technology incorporates hundreds of thousands of CXRs into a convoluted neural network and is generally named AI CXR. As an example, the AUROC (Area Under Receiving Operator Characteristic) of screening for T2DM was 0.84, with sensitivity and specificities that exceed those of the United States Preventative Services Task Force (USPSTF) guidelines for screening with HBA1c or blood glucose studies. The AUROC's for diagnosing ejection fractions less than 40% was 0.92, and for detecting valvular heart diseases was 0.87. The potential implications for underwriting life and disability policies may be significant. A companion article in the Journal of Insurance Medicine addresses this same technology using a simple 12-lead ECG, generally named AI ECGs.

人工智能(AI)深度学习模型在临床疾病筛查中的应用不断发展。本论文提供的实例包括使用简单的单视角 PA 胸片筛查 2 型糖尿病 (T2DM)、充血性心力衰竭、瓣膜性心脏病,以及评估无症状呼吸系统疾病患者的死亡率。这项技术将数十万张 CXR 纳入一个复杂的神经网络,一般被命名为 AI CXR。例如,筛查 T2DM 的 AUROC(接收操作者特征下面积)为 0.84,灵敏度和特异性都超过了美国预防服务工作组(USPSTF)关于使用 HBA1c 或血糖研究进行筛查的指南。诊断射血分数低于 40% 的 AUROC 为 0.92,检测瓣膜性心脏病的 AUROC 为 0.87。这对人寿保险和残疾保险的承保可能会产生重大影响。保险医学杂志》(Journal of Insurance Medicine)上的另一篇文章使用简单的 12 导联心电图(一般称为人工智能心电图)探讨了相同的技术。
{"title":"Through the Looking Glass Darkly: How May AI Models Influence Future Underwriting?","authors":"Rodney C Richie","doi":"10.17849/insm-51-2-59-63.1","DOIUrl":"https://doi.org/10.17849/insm-51-2-59-63.1","url":null,"abstract":"<p><p>Applications of Artificial Intelligence (AI) deep-learning models to screening for clinical conditions continue to evolve. Instances provided in this treatise include using a simple one-view PA chest radiograph to screen for Type 2 Diabetes Mellitus (T2DM), congestive heart failure, valvular heart disease, and to assess mortality in asymptomatic persons with respiratory diseases. This technology incorporates hundreds of thousands of CXRs into a convoluted neural network and is generally named AI CXR. As an example, the AUROC (Area Under Receiving Operator Characteristic) of screening for T2DM was 0.84, with sensitivity and specificities that exceed those of the United States Preventative Services Task Force (USPSTF) guidelines for screening with HBA1c or blood glucose studies. The AUROC's for diagnosing ejection fractions less than 40% was 0.92, and for detecting valvular heart diseases was 0.87. The potential implications for underwriting life and disability policies may be significant. A companion article in the Journal of Insurance Medicine addresses this same technology using a simple 12-lead ECG, generally named AI ECGs.</p>","PeriodicalId":39345,"journal":{"name":"Journal of insurance medicine (New York, N.Y.)","volume":"51 2","pages":"59-63"},"PeriodicalIF":0.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142297627","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of insurance medicine (New York, N.Y.)
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1